Immunotherapy for cSCC, This program will include a discussion of

Download this Presentation


Presentation Transcript

  • 1.Immunotherapy for cSCC
  • 2.This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.
  • 3.Introduction
  • 4.Treatment Options for Locally Advanced cSCC
  • 5.Clinical Features and Diagnosis
  • 6.Precancerous Actinic Keratoses
  • 7.Squamous Cell Carcinomas
  • 8.Advanced cSCC
  • 9.Role of Practitioners in Disease Identification
  • 10.Risk Factors
  • 11.Risk Factors to Watch
  • 12.Considerations for Therapy
  • 13.Current Treatment Options
  • 14.Which Patients Are Candidates for Immunotherapy?
  • 15.How Do Risks Factors Affect Pathophysiology?
  • 16.Overview of Immune Checkpoint Response
  • 17.Immune Checkpoint Pathway
  • 18.Immune Checkpoint Blockade
  • 19.Rationale for Checkpoint Inhibitor Studies
  • 20.Phase 1: Cemiplimab (REGN2810)Study Design
  • 21.Phase 1: Cemiplimab (REGN2810)Patient Population and Response
  • 22.Phase 2Cemiplimab
  • 23.Ongoing Checkpoint Inhibitor Trials in cSCC
  • 24.Concluding Remarks
  • 25.Abbreviations
  • 26.Abbreviations (cont)